Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Cerus Leads Our Selection Of 3 Promising Penny Stocks

In This Article:

As U.S. stocks attempt to recover from recent downturns, with the S&P 500 and Nasdaq aiming to end their losing streaks, investors are navigating a market filled with uncertainty yet ripe with potential opportunities. Penny stocks, though often overlooked in favor of more established names, remain an intriguing investment area for those seeking growth in smaller or newer companies. By focusing on firms with strong financial foundations and clear paths to growth, investors can uncover promising prospects within this niche segment of the market.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

Safe Bulkers (NYSE:SB)

$3.82

$403.65M

★★★★☆☆

Tuya (NYSE:TUYA)

$3.57

$2.28B

★★★★★★

Peraso (NasdaqCM:PRSO)

$0.8062

$2.92M

★★★★★☆

Sensus Healthcare (NasdaqCM:SRTS)

$4.74

$78.85M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

TETRA Technologies (NYSE:TTI)

$3.41

$454.11M

★★★★☆☆

Imperial Petroleum (NasdaqCM:IMPP)

$2.59

$77.35M

★★★★★★

BAB (OTCPK:BABB)

$0.84

$6.03M

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$136.47M

★★★★★★

CBAK Energy Technology (NasdaqCM:CBAT)

$0.8281

$76.45M

★★★★★☆

Click here to see the full list of 765 stocks from our US Penny Stocks screener.

Let's dive into some prime choices out of the screener.

Cerus

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Cerus Corporation is a biomedical products company with a market cap of $284.26 million.

Operations: The company generates revenue from its Blood Safety segment, amounting to $180.27 million.

Market Cap: $284.26M

Cerus Corporation, with a market cap of US$284.26 million, is noteworthy in the penny stock space for its stable revenue stream from the Blood Safety segment, totaling US$180.27 million. Despite being unprofitable with a net loss of US$20.92 million in 2024, it has reduced losses significantly over five years and maintains a satisfactory net debt to equity ratio of 6.5%. The company's short-term assets exceed both short and long-term liabilities, providing financial stability amidst its growth trajectory forecasted at 12.28% annually. However, significant insider selling may warrant caution for potential investors.

NasdaqGM:CERS Revenue & Expenses Breakdown as at Mar 2025
NasdaqGM:CERS Revenue & Expenses Breakdown as at Mar 2025

Navitas Semiconductor

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Navitas Semiconductor Corporation designs, develops, and markets gallium nitride power integrated circuits and related technologies for power conversion and charging, with a market cap of approximately $482.04 million.